Transition of Indian pharma from traditional to newer dosage formats

Pharmaceutical industry has been continuously evolving and innovating in its approach to provide medical solutions benefiting patients. In the last few years, a new era of science and technology has emerged in pharmaceutical research with focus on developing novel drug delivery systems for oral administration. Conventional dosage forms like tablets and capsules are associated with a low bioavailability, frequent application, side effects and hence patient noncompliance.  “To liberate…
Read More…

Source: https://etinsights.et-edge.com/transition-of-indian-pharma-from-traditional-to-newer-dosage-formats/amp/

Empowering Pharmacies with AI-Driven Cash Pricing

What You Should Know:

– Prescryptive Health, a leading healthcare technology company, today announced the National Community Pharmacists Association’s (NCPA) renewed endorsement of Prescryptive AI Pricing. 

– Prescryptive AI Pricing creates a dynamic and competitive cash pricing system, enabling independent pharmacies to thrive in the ever-evolving healthcare landscape. This AI-powered solution empowers independent pharmacies to optimize cash pricing and enhance their…
Read More…

Source: https://hitconsultant.net/2024/05/02/ncpa-renews-recommendation-of-prescryptive-ai-pricing/

Shanghai Shyndec Pharmaceutical First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Shanghai Shyndec Pharmaceutical (SHSE:600420) First Quarter 2024 ResultsKey Financial Results Revenue: CN¥3.12b (down 8.6% from 1Q 2023). Net income: CN¥331.3m (up 85% from 1Q 2023). Profit margin: 11% (up from 5.2% in 1Q 2023). The increase in margin was driven by lower expenses. EPS: CN¥0.25 (up from CN¥0.15 in 1Q 2023). SHSE:600420 Earnings and Revenue Growth May 2nd 2024 All figures shown in the chart above are for the trailing 12 month (TTM) period Shanghai Shyndec Pharmaceutical…
Read More…

Source: https://simplywall.st/stocks/cn/pharmaceuticals-biotech/shse-600420/shanghai-shyndec-pharmaceutical-shares/news/shanghai-shyndec-pharmaceutical-first-quarter-2024-earnings

“3 Key Trends” With Rob Feltz

What are “3 Key Trends” shaping the CDMO industry in 2024 and beyond? Sharp Services’ director of analytical and formulation services, Rob Feltz, shares his thoughts with Contract Pharma.The rise of digital transformation and AI
As we delve into the digital transformation and AI’s role within the pharmaceutical industry, it’s crucial to highlight the multifaceted impact of these technologies:Investment in digital innovations
The trend towards digitalization is evident,…
Read More…

Source: https://www.contractpharma.com/contents/view_online-exclusives/2024-05-01/3-key-trends-with-rob-feltz/

Independent pharmacy to takeover from Boots in Appleby

Eden Pharmacy, which is part of The Green Tree Pharmacy based in Kirkby Stephen, will be taking over the national chain on 11 Boroughgate as of June 3. 

In a post on social media, a spokesperson said: “We will be taking over Boots Pharmacy at Appleby-in-Westmorland on June 3, 2024.  We will be changing its name back to Eden Pharmacy.

“Appreciate there will be a lot of confusion but please bear with us. We will get it up and running as smoothly as possible,” they said. 


Read More…

Source: https://www.newsandstar.co.uk/news/24288698.independent-pharmacy-takeover-boots-appleby/

Beckman Coulter Life Sciences and Watchmaker Genomics Collaborate

1 May 2024
08:07

Beckman Coulter Life Sciences has entered a collaborative partnership with Watchmaker Genomics for high-stringency clinical and translational applications. The partnership harnesses the value of each organisation to deliver robust and reliable automated liquid handling solutions that enable labs to streamline operations and generate consistent results.

As part of the agreement, the two…
Read More…

Source: https://pharmaceuticalmanufacturer.media/api/amp/pharma-manufacturing-news/latest-pharmaceutical-manufacturing-news/beckman-coulter-life-sciences-and-watchmaker-genomics-collab/